Meta-ranalysis: Serum Visfatin In The Patients With Polycystic Ovarian Syndrome

Objective: Polycystic ovarian syndrome(PCOS) is a common gynecological clinic and clinical disease. These patients generally have endocrine and metabolic disorders, manifested as insulin resistance and weight gain due to glucose and lipid metabolism disorders. PCOS often have menstrual disorders(amenorrhea or oligohypomenorrhea), infertility, obesity, hersutism and bilateral ovary become cystic larger as clinical performance. PCOS is one of the main reason which couse ovulatory and infertility. And its incidence is increasing year by year, and the risk of hypertension, hyperlipidemia, diabetes and endometrial cancer are increased in these patients, that may seriously affect people's physical and mental health.Visfatin is a newly found adipokine, which was isolated and named from the visceral adipose tissue by Japanese scholars Fukuhara in 2005. It's protein structure is consistent with the protein known as the former B cell clone enhancement factor(PBEF) isolated from lymphocytes by American scholars in 1994. Study found that visfatin plays a role of reduce blood glucose and simulate insulin, through the activation of insulin signal pathway, inducing receptor and substrate phosphorylation. However, there are still controversies about serum visfatin levels are related to insulin resistance or not. But visfatin has been proved to be an independent risk factor in type 2 diabetes. Visfatin is closely related to obesity and metabolic syndrome. Visfatin expression is increased in the obese population, mainly in the macrophages of visceral white adipose tissue. And visfatin expression decreased when weight loss and body fat reduced.This meta analysis comprehensive study the serum visfatin levels in the patients with polycystic ovary syndrome, assess the relationship between visfatin and PCOS, find new targets for the clinical treatmen of PCOS. Methods: Four database including CNKI, Wan Fang, VIP and PubMed were searched for a period between October 2003 and March 2011 to collect case——published research literature of the relationshipe beween serum visfatin level and polycystic ovary syndrome, extracted data from selected documents, applications Review Manager 4.2 software for data processing.Results: This study includes 8 literature which include a total of 536 subjects, 278 subjects with polycystic ovary syndrome and 258 controls. These 8 studies were statistically heterogeneous(χ~2=586.43,df=7,P<0.00001), so random effects model for combined analysis was used. Meta analysis showed that serum visfatin level was significantly higher in the group with polycystic ovary syndrome than that in controls, the difference has statistically significance[WHD=0.24,95%CI(0.13,0.34),P<0.00001].Conclusion: Serum visfatin levels in patients with polycystic ovary syndrome were significantly higher than the normal control group, the difference has statistically significance.